Genentech and AC Immune partner again
Enlarge image


Genentech and AC Immune partner again

19.06.2012 - Six years after their first alliance, Swiss AC Immune SA partners again with US-American Genentech Inc.

Basel/Lausanne – The subject of the new cooperation remained the same: fighting Alzheimer's disease. Therefore the Roche subsidiary has now in-licensed a second generation of AC Immune's antibodies - this time directed to bind the Tau protein. Under the terms of the agreement, AC Immune will receive an undisclosed upfront payment and research, development and commercialisation milestone payments totalling more than CHF400m. Additionally, AC Immune could pocket royalties on net sales resulting from the collaboration – if the product is approved.

Under the multi-year joint research collaboration, AC Immune will work in partnership with Genentech to identify and formulate several pre-clinical candidates. The pharma will have global responsibility for pre-clinical and clinical development, manufacturing and commercialisation of antibodies resulting from the collaboration. Scientifically, both partners are building on the first alliance as the new Tau antibodies are thought to flank Crenezumab, an antibody in phase II resulting from the first cooperation that binds amyloid-beta-plaques (abeta).

By blocking Tau- fibrillation and destroying abeta aggregates, AC Immune attacks the two crucial steps in Alzheimer development. AC Immune has raised CHF64m since its foundation in 2003. Financiers are business angels from Switzerland and prominent biotech supporters like Dietmar Hopp, the founder of the German business software maker SAP. Beside the out- licensed antibody projects, AC immune develops a proprietary small molecule pipeline


24.11.2015 After weeks of speculation it is official: US pharma major Pfizer and Irish Botox maker Allergan will merge. With the deal, Pfizer is planning to dodge the high US taxes, causing indignation among US politicians.


23.11.2015 Amidst talk of the IPO window closing and cancelled flotations, diagnostics firms are still striking a chord with investors. Swedish Immunovia and German Curetis are successfully raising public money.


20.11.2015 French Sanofi and British AstraZeneca are giving open innovation a go: The two pharma giants will exchange thousands of compounds – for free.


19.11.2015 French gene editing company Cellectis has granted Servier the rights to bring cancer immunotherapy UCART19 to market. Servier in turn has teamed up with Pfizer to hurry development along.


17.11.2015 The first Italian accelerator specifically for biotech projects has been launched with help from Sofinnova Partners. The plan of BiovelocITA: to help Italy grow into one of Europe’s strongest biotech markets.


13.11.2015 Scientists in Bath, UK, have developed a medical dressing that turns fluorescent green when it detects infection. The researchers hope that the smart burns dressing will help fight antibiotic resistance.


13.11.2015 Out with the old: Roche is discarding four sites with 1,200 staff in an effort to restructure its manufacturing network for small molecules. Instead, a new manufacturing site will be built in Switzerland.


10.11.2015 Algae have many skills, but cancer fighting was not one of them – until now. Researchers from Australia and Germany have genetically engineered diatom algae to accurately deliver chemotherapeutic drugs.


10.11.2015 AstraZeneca has plucked Californian biopharma company ZS Pharma from under Actelion’s nose. The UK company is paying US$2.7bn (€2.5bn) to acquire ZS and its promising hyperkalaemia treatment currently under US regulatory review.


04.11.2015 What biotech stock market slump? Despite all odds, 2015 is set to become a new record year for the European public biotech sector, according to a BIOCOM-study presented at BIO Europe in Munich.


All Events


Strasbourg (F)

BioFIT 2015

Current issue

All issues

Product of the week


Stock list

All quotes


  • THERAMETRICS (CH)0.05 CHF25.00%
  • MOLOGEN (D)4.10 EUR13.89%


  • DIAMYD MEDICAL -B- (S)8.75 SEK-5.91%
  • IMMUNICUM AB (S)40.60 SEK-5.80%
  • CELLECTIS (F)29.57 EUR-5.07%


  • PLETHORA (UK)5.50 GBP76.3%
  • PROTHENA PLC (IE)73.20 USD46.1%
  • CELLECTIS (F)29.57 EUR27.9%


  • EPIGENOMICS (D)1.84 EUR-59.3%
  • EVOCUTIS (UK)0.10 GBP-33.3%


  • KARO BIO (S)37.50 SEK5181.7%
  • CHRONTECH PHARMA (S)0.34 SEK1600.0%
  • GALAPAGOS (B)44.82 EUR249.1%


  • BIOTEST (D)15.03 EUR-81.4%
  • NEOVACS (F)0.72 EUR-79.1%

No liability assumed, Date: 25.11.2015